<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739306</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P42 3.1</org_study_id>
    <nct_id>NCT04739306</nct_id>
  </id_info>
  <brief_title>Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema</brief_title>
  <official_title>A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to&#xD;
      Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic&#xD;
      Macular Edema&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical response in Best Corrected Visual Acuity using Early Treatment of Diabetic Retinopathy Study chart</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetic Macular Edema (DME)</condition>
  <arm_group>
    <arm_group_label>CT-P42</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P42</intervention_name>
    <description>2mg/0.05 mL by Intravitreal injection</description>
    <arm_group_label>CT-P42</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eylea</intervention_name>
    <description>2mg/0.05 mL by Intravitreal injection</description>
    <arm_group_label>Eylea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient aged â‰¥18 years.&#xD;
&#xD;
          -  Patient with DME secondary to DM involving the center of the macula (defined as the&#xD;
             Optical Coherence Tomography [OCT] central subfield) in the study eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has only one functional eye.&#xD;
&#xD;
          -  Patient who currently has, or has a history (where indicated) of active proliferative&#xD;
             diabetic retinopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MiSun Lee</last_name>
    <phone>+82 32 850 5742</phone>
    <email>misun.lee@celltrion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ByeongHyeon Kim</last_name>
    <phone>+82 32 850 5745</phone>
    <email>byeonghyeon.kim@celltrion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>II. Ocna klinika SZU, F.D.Roosevelt Hospital</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

